Evidence map›Paper›PMID 42584177›Full record

SynthesisClinical obesity2026

Burden and Risk of Depression in Patients Receiving Semaglutide: A Systematic Review and Meta-Analysis.

Gaurab Bhaduri, Shilanjan Roy, Anchin Kalia, Rutul Gokalani, Banshi Saboo

Abstract readSystematic ReviewMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Clinical obesity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Gaurab BhaduriDepartment of Diabetes & Endocrinology, Park View Super Speciality Hospital, Kolkata, West Bengal, India.ORCID https://orcid.org/0009-0007-4000-9287
Shilanjan RoyCharnock Hospital, Kolkata, West Bengal, India.ORCID https://orcid.org/0009-0009-4257-9982
Anchin KaliaDepartment of Medicine, Mahatma Gandhi Medical College and Hospital, Jaipur, Rajasthan, India.ORCID https://orcid.org/0000-0001-8869-9351
Rutul GokalaniAHC Diabetes Centre, Ahmedabad, Gujarat, India.ORCID https://orcid.org/0000-0001-8546-002X
Banshi SabooDiaCare, Diabetes Care & Hormone Clinic, Ahmedabad, Gujarat, India.ORCID https://orcid.org/0000-0001-7293-8864

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), including semaglutide, are widely used for Type 2 diabetes mellitus (T2DM), obesity and related metabolic conditions. Evidence on potential neuropsychiatric effects remains inconsistent. This systematic review and meta-analysis evaluated depression risk among patients receiving semaglutide. Following PRISMA 2020 guidelines, major biomedical databases, trial registries, pharmacovigilance databases, conference abstracts and grey literature were searched from inception to January 2026. Eligible studies included randomised controlled trials, observational studies, large database analyses and pharmacovigilance disproportionality studies involving patients receiving semaglutide. Risk of bias was assessed using ROBINS-I and the Newcastle-Ottawa Scale. The pooled risk ratio for depression was 1.25 (95% CI: 0.95-1.65; I

Indexed as

DepressionDiabetes Mellitus, Type 2Glucagon-Like PeptidesHypoglycemic AgentsGlucagon-Like Peptide-1 Receptor AgonistsHumansRisk FactorsSemaglutideGlucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like PeptidesHypoglycemic AgentsSemaglutidedepressionGLP‐1RArisk factorssemaglutide

Identifiers

PMID42584177
PMCPMC13464048

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.